Or wait…
Headlines
Bio Developments
Upstream Processing
Downstream Processing
Markets & Regulations
Biopharma Culture
Promotional Features
Site Archive
Multimedia
Hot Topics
Biosimilars
COVID-19
Pipelines
Antibody-Drug Conjugates
Emerging Markets
Cell & Gene Therapies
Site Archive
Multimedia
Resources
Type of resources
Events
All Events
Online Events
Editorial Webinars
Shows & Conferences
Events
Related Site
By Staff Reporter
– Last updated on GMT
Related tags: Pharmacology
Speaking with this publication in 2013, XstalBio’s then CSO Barry Moore said the centrifuge-based CentuRecon platform offered an alternative to the traditional “manual swirling” method used by drug companies to reconstitute a product from a lyophilised state.
This “would typically take at least 30-40 minutes of manual swirling to make a 200 mg/ml solution,” and “is likely to have some foam on top of it which may reduce the volume that can be injected.”
He added that by using a centrifuge to remove adsorbed air bubbles from a suspended powder, the CentuRecon platform can produce an injectable, foam-free solution within a fraction of the time.
Now, according to Nat Baldwin at commercial intellectual property consulting company Metis Partners, the numerous patent applications underpinning the CentuRecon technology are available to buy.
“The company entered liquidation a few months ago and the liquidators are now looking to realise its assets,” he told Biopharma-Reporter.
“We think the technology may be of interest to the pharma, and particularly biologic pharmaceuticals, space as well as medical device developers and manufacturers, with a specific focus on centrifuge and syringe producers.”
As for the price, he told us “no minimum offer level has been set at this stage” and has invited interested parties to submit an offer by noon GMT tomorrow.
Copyright - Unless otherwise stated all contents of this web site are © 2022 - William Reed Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Related topics: Fill-Finish & Packaging, Separation & Purification, Downstream Processing, Bio-Outsourcing
Show more
The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...
Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...
At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...
Upcoming editorial webinars
On-demand webinars
More promotional features
